4 recruiting, 4 unknown, 3 completed, 2 active not recruiting. 8 Phase 2, 2 Phase 3, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Recruiting 4, Unknown 3, Active not recruiting 1 |
| Phase 3 | 2 | Recruiting 1, Terminated 1 |
| Not applicable | 1 | Unknown 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Metastatic Esophageal Squamous Cell Carcinoma: new trials by email Literature Review of Metastatic Esophageal Squamous Cell Carcinoma trials Research Report on Metastatic Esophageal Squamous Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC Tislelizumab, Oxaliplatin, Leucovorin - Advanced Esophageal Squamous Cell Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma | Phase 2 | Recruiting | BeOne Medicines | 30 | 2026-09-14 | 2026-10-26 |
| Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program Home Health Encounter, Nivolumab, Patient Monitoring - Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 50 | 2024-04-30 | 2026-10-02 |
| Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer TP regimen (cis-platinum ; Tocetaxel ) combined with PD-1 inhibitors（Sintilimab） - Metastatic Esophageal Squamous Cell Carcinoma | Phase 2 / Phase 3 | Recruiting | Qingdao Central Hospital | 90 | 2023-09-20 | 2024-07-24 |
| A Study of IO Plus Radiotherapy in Patients With Advanced ESCC. Radiotherapy - Metastatic Esophageal Squamous Cell Carcinoma | Not applicable | Unknown | Fudan University | 100 | 2023-02-28 | 2023-07-25 |
| Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma LDRT+CFRT, Immunotherapy, Chemotherapy - Esophageal Squamous Cell Carcinoma, Esophageal Cancer | Phase 2 | Recruiting | Shanghai Chest Hospital | 100 | 2023-01-01 | 2026-01-22 |
| AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC AK104, Cisplatin, Paclitaxel - Unresectable Esophageal Squamous Cell Carcinoma, Locally Advanced Esophageal Squamous Cell Carcinoma | Phase 2 | Unknown | Chinese Academy of Medical Sciences | 80 | 2022-10-01 | 2022-08-31 |
| Concurrent Chemoradiotherapy for Stage IVB Esophageal Squamous Cell Carcinoma（EC-CRT-003） Intensity-modulated radiotherapy concurrent with capecitabine - Metastatic Esophageal Squamous Cell Carcinoma | Phase 2 | Unknown | Sun Yat-sen University | 126 | 2022-09-20 | 2023-11-18 |
| Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC. Anti-PD-1 Immune Checkpoint Inhibitors - Metastatic Esophageal Squamous Cell Carcinoma | Completed | Fudan University | 1197 | 2021-10-31 | 2026-02-05 | |
| Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014). Pembrolizumab, Lenvatinib, Cisplatin - Metastatic Esophageal Squamous Cell Carcinoma | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 863 | 2021-07-28 | 2026-08-21 |
| Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers Adavosertib, Radiation Therapy - Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8 | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 4 | 2021-04-09 | 2026-07-31 |
| The Ave-CRT Study for Newly Diagnosed Metastatic Esophageal Squamous Cell Carcinoma Avelumab - Esophageal Tumor, Metastatic Esophageal Squamous Cell Carcinoma | Phase 2 | Unknown | National Taiwan University Hospital | 26 | 2019-03-20 | 2021-09-08 |
| Real-world Experience of ICIs Plus Chemotherapy With or Without Radiotherapy for Advanced ESCC. Chemotherapy combined with immunotherapy, radiotherapy - Metastatic Esophageal Squamous Cell Carcinoma | Completed | Tianjin Medical University Cancer Institute and Hospital | 728 | 2018-10-13 | 2024-02-05 | |
| Prognostic Factor Analysis in Metastatic Esophageal Squamous Cell Carcinoma Metastatic Esophageal Squamous Cell Carcinoma | Completed | Samsung Medical Center | 239 | 2012-03-01 | 2013-04-09 | |
| Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer Cixutumumab, Laboratory Biomarker Analysis, Paclitaxel - Metastatic Esophageal Adenocarcinoma, Metastatic Esophageal Squamous Cell Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 94 | 2010-09-21 | 2026-09-10 |
Esophageal Squamous Cell Carcinoma (14) · Esophageal Neoplasms (4) · Adenocarcinoma Of Esophagus (2) · Brain Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Colorectal Neoplasms (1) · Melanoma (1) · Meningeal Carcinomatosis (1) · Parkinson Disease 4, Autosomal Dominant Lewy Body (1) · Squamous Cell Carcinoma of Head and Neck (1)
Carcinoma (14) · Carcinoma, Squamous Cell (14) · Digestive System Diseases (14) · Digestive System Neoplasms (14) · Esophageal Diseases (14) · Gastrointestinal Diseases (14) · Gastrointestinal Neoplasms (14) · Head and Neck Neoplasms (14) · Neoplasms (14) · Neoplasms by Histologic Type (14) · Neoplasms by Site (14) · Neoplasms, Glandular and Epithelial (14) · Neoplasms, Squamous Cell (14) · Esophageal Neoplasms (10) · Adenocarcinoma (1)
Cisplatin (3) · Paclitaxel (3) · Radiotherapy (3) · Fluorouracil (2) · Immunotherapy (2) · Leucovorin (2) · Oxaliplatin (2) · Capecitabine (1) · Drug Therapy (1) · Home Care Services (1) · House Calls (1) · Levoleucovorin (1) · Nivolumab (1) · Radiation (1) · Remote Patient Monitoring (1)
Fudan University (2) · National Cancer Institute (NCI) (2) · BeOne Medicines (1) · Chinese Academy of Medical Sciences (1) · Mayo Clinic (1) · Merck Sharp & Dohme LLC (1) · National Taiwan University Hospital (1) · Qingdao Central Hospital (1) · Samsung Medical Center (1) · Shanghai Chest Hospital (1) · Sun Yat-sen University (1) · Tianjin Medical University Cancer Institute and Hospital (1)
China (7) · United States (4) · Japan (2) · Taiwan (2) · Argentina (1) · Canada (1) · Chile (1) · Costa Rica (1) · Denmark (1) · France (1) · Guatemala (1) · Hong Kong (1) · Hungary (1) · Italy (1) · Malaysia (1)
Chia-Hsien Cheng (1) · Eric D Miller (1) · Jeeyun Lee, M.D., Ph.D. (1) · Jing Huang, M.D. (1) · Kuaile Zhao, M.D. (1) · Lvhua Wang, M.D. (1) · Roxana S. Dronca, M.D. (1) · Steven J Cohen (1) · Wen Yu, M.D (1) · Wencheng Zhang, M.D. (1)
PMID 37104870, PMID 37937444, PMID 38695479, PMID 41167638, PMID 41696558
U10CA021115 (1), U10CA180820 (1), UM1CA186712 (1)